Outfitter Financial LLC Acquires 205 Shares of Boston Scientific Co. (NYSE:BSX)

Outfitter Financial LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,317 shares of the medical equipment provider’s stock after purchasing an additional 205 shares during the quarter. Boston Scientific comprises approximately 1.7% of Outfitter Financial LLC’s holdings, making the stock its 21st largest position. Outfitter Financial LLC’s holdings in Boston Scientific were worth $1,926,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after buying an additional 8,045,263 shares during the period. American Century Companies Inc. grew its holdings in shares of Boston Scientific by 391.6% during the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock worth $172,752,000 after purchasing an additional 2,606,253 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Boston Scientific by 5.9% during the third quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after purchasing an additional 2,336,348 shares during the period. Winslow Capital Management LLC lifted its position in Boston Scientific by 39.3% in the third quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider’s stock worth $323,641,000 after purchasing an additional 1,730,133 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Boston Scientific by 1.2% during the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after buying an additional 1,525,432 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.4 %

BSX traded down $0.29 during mid-day trading on Friday, reaching $73.81. The stock had a trading volume of 1,319,716 shares, compared to its average volume of 6,531,991. The firm’s fifty day simple moving average is $68.95 and its two-hundred day simple moving average is $61.90. The stock has a market capitalization of $108.29 billion, a P/E ratio of 62.08, a P/E/G ratio of 2.51 and a beta of 0.77. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. TD Cowen increased their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Deutsche Bank Aktiengesellschaft increased their target price on Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a report on Thursday, April 25th. Evercore ISI boosted their price target on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Finally, Needham & Company LLC increased their price objective on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.09.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,330 shares of company stock worth $5,682,434. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.